Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186680 · ClinicalTrials.gov registry record · Phase 1
CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT00186680: Completed Phase 1 study, sponsored by Stanford University.
NCT00186680 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 99 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186680, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.
Interventions
- PROCEDURE high dose chemo then auto hematopoietic cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 1996-09 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186680
The ClinicalTrials.gov registry entry for NCT00186680 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which high dose chemo then auto hematopoietic cell transplant is the first listed.
NCT00186680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186680 about?
NCT00186680 is a clinical study titled "CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant". Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.
What is the current status of trial NCT00186680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 1996-09. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00186680?
The interventions under investigation include: high dose chemo then auto hematopoietic cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00186680?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.